1. Name Of The Medicinal Product
Canesten 200mg Pessary.
2. Qualitative And Quantitative Composition
Clotrimazole 200mg
For excipients, see 6.1
3. Pharmaceutical Form
Pessary
4. Clinical Particulars
4.1 Therapeutic Indications
Canesten 200mg Pessaries are recommended for the treatment of candidal vaginitis.
4.2 Posology And Method Of Administration
The pessaries should be inserted into the vagina, as high as possible, using the applicator provided. This is best achieved when lying back with legs bent up.
Adults:
One pessary should be inserted daily (preferably at night) for three consecutive days. A second treatment may be carried out if necessary.
There is no separate dosage schedule for the elderly.
Canesten pessaries need moisture in the vagina in order to dissolve completely, otherwise undissolved pieces of the pessary might crumble out of the vagina. Pieces of undissolved pessary may be noticed by women who experience vaginal dryness. To help prevent this it is important that the pessary is inserted as high as possible in to the vagina at bedtime.
Generally:
treatment during the menstrual period should not be performed due to the risk of the pessary being washed out by the menstrual flow. The treatment should be finished before the onset of menstruation.
Do not use tampons, intravaginal douches, spermicides or other vaginal products while using this product.
Children:
Not for use in children under 16.
4.3 Contraindications
Hypersensitivity to clotrimazole or any of the excipients in this product.
4.4 Special Warnings And Precautions For Use
Medical advice should be sought if this is the first time the patient has experienced symptoms of candidal vaginitis.
Before using Canesten 200mg Pessaries, medical advice must be sought if any of the following are applicable:
- more than two infections of candidal vaginitis in the last six months.
- previous history of a sexually transmitted disease or exposure to partner with sexually transmitted disease.
- pregnancy or suspected pregnancy.
- aged under 16 or over 60 years.
- known hypersensitivity to imidazoles or other vaginal anti-fungal products.
Canesten 200mg Pessaries should not be used if the patient has any of the following symptoms whereupon medical advice should be sought:
- irregular vaginal bleeding.
- abnormal vaginal bleeding or a blood-stained discharge.
- vulval or vaginal ulcers, blisters or sores.
- lower abdominal pain or dysuria.
- any adverse events such as redness, irritation or swelling associated with the treatment.
- fever or chills.
- nausea or vomiting.
- diarrhoea.
- foul smelling vaginal discharge.
Patients should be advised to consult their physician if the symptoms have not been relieved within one week of using Canesten 200mg Pessaries. The pessaries can be used again if the candidal infection returns after 7 days. However, if the candidal infection recurs more than twice within six months, patients should be advised to consult their physician.
4.5 Interaction With Other Medicinal Products And Other Forms Of Interaction
Laboratory tests have suggested that, when used together, this product may cause damage to latex contraceptives. Consequently, the effectiveness of such contraceptives may be reduced. Patients should be advised to use alternative precautions for at least five days after using this product.
Concomitant medication with vaginal clotrimazole and oral tacrolimus (FK-506; immunosuppressant) might lead to increased tacrolimus plasma levels. Patients should thus be closely monitored for signs and symptoms of tacrolimus overdosage, if necessary by determination of the respective plasma levels.
4.6 Pregnancy And Lactation
Data on a large number of exposed pregnancies indicate no adverse effects of Clotrimazole on pregnancy or on the health of the foetus/newborn child. To date, no relevant epidemiological data are available.
Clotrimazole can be used during pregnancy, but only under the supervision of a physician or midwife.
During pregnancy the pessary should be inserted without using an applicator.
4.7 Effects On Ability To Drive And Use Machines
Not applicable.
4.8 Undesirable Effects
As the listed undesirable effects are based on spontaneous reports, assigning accurate frequency of occurrence for each is not possible.
Immune system disorders:
allergic reaction (syncope, hypotension, dyspnea, urticaria, pruritus)
Reproductive system and breast disorders:
genital peeling, pruritus, rash, oedema, discomfort, burning, irritation, pelvic pain
Gastrointestinal disorders:
abdominal pain
4.9 Overdose
In the event of accidental oral ingestion, routine measures such as gastric lavage should be performed only if clinical symptoms of overdose become apparent (e.g. dizziness, nausea or vomiting). It should be carried out only if the airway can be protected adequately.
5. Pharmacological Properties
5.1 Pharmacodynamic Properties
ATC Code: G01A F02
Clotrimazole is an imidazole derivative with a broad spectrum of antimycotic activity.
Mechanism of Action
Clotrimazole acts against fungi by inhibiting ergosterol synthesis. Inhibition of ergosterol synthesis leads to structural and functional impairment of the cytoplasmic membrane.
Pharmacodynamic Effects
Clotrimazole has a broad antimycotic spectrum of action in vitro and in vivo, which includes dermatophytes, yeasts, moulds, etc.
The mode of action of clotrimazole is fungistatic or fungicidal depending on the concentration of clotrimazole at the site of infection. In-vitro activity is limited to proliferating fungal elements; fungal spores are only slightly sensitive.
Primarily resistant variants of sensitive fungal species are very rare; the development of secondary resistance by sensitive fungi has so far only been observed in very isolated cases under therapeutic conditions.
5.2 Pharmacokinetic Properties
Pharmacokinetic investigations after vaginal application have shown that only a small amount of clotrimazole (3 – 10% of the dose) is absorbed. Due to the rapid hepatic metabolism of absorbed clotrimazole into pharmacologically inactive metabolites the resulting peak plasma concentrations of clotrimazole after vaginal application of a 500mg dose were less than 10 ng/ml, reflecting that clotrimazole applied intravaginally does not lead to measurable systemic effects or side effects.
5.3 Preclinical Safety Data
There are no pre-clinical data of relevance to the prescriber which are additional to the information included in other sections of the SPC.
6. Pharmaceutical Particulars
6.1 List Of Excipients
Calcium lactate pentahydrate
Maize starch
Crospovidone
Silica, colloidal anhydrous
Lactic acid
Lactose Monohydrate
Magnesium Stearate
Hypromellose
Cellulose, microcrystalline
6.2 Incompatibilities
Not applicable.
6.3 Shelf Life
48 months.
6.4 Special Precautions For Storage
No special precautions for storage
6.5 Nature And Contents Of Container
Three pessaries are packed in a blister pack (foil 25µm PA + 45µm Al soft + 60µm PVC) sealed with aluminium backing foil (foil 20µm Al hard + 7g/m2 HSL sealable to PVC/PVDC). An applicator is also provided.
The pessaries and applicator are enclosed in a cardboard carton.
6.6 Special Precautions For Disposal And Other Handling
|
|
7. Marketing Authorisation Holder
Bayer plc
Bayer House
Strawberry Hill
Newbury, Berkshire
RG14 1JA
Trading as Bayer plc, Consumer Care Division
8. Marketing Authorisation Number(S)
PL 0010/0072
9. Date Of First Authorisation/Renewal Of The Authorisation
Date of first authorisation: 21 September 1979
Date of last renewal of authorisation: 10 November 1999
10. Date Of Revision Of The Text
12/08/2010
LEGAL CATEGORY
P
No comments:
Post a Comment